Etofenamate

Identification

Name
Etofenamate
Accession Number
DB08984
Type
Small Molecule
Groups
Experimental
Description

Etofenamate is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of joint and muscular pain.

Structure
Thumb
Synonyms
  • Etofenamate
External IDs
BAY D 1107 / BAY-D-1107 / TVX-485 / TVX485 / WHR-5020
International/Other Brands
Activon (Meda) / Aspitopic (Bayer) / Bayagel (Bayer) / Bayro (Bayer) / Etobay (Bayer) / Gemadol (Meda) / Glasel (Meda) / Rheumon (Bayer) / Ticatrop (Meda)
Categories
UNII
KZF0XM66JC
CAS number
30544-47-9
Weight
Average: 369.335
Monoisotopic: 369.118792684
Chemical Formula
C18H18F3NO4
InChI Key
XILVEPYQJIOVNB-UHFFFAOYSA-N
InChI
InChI=1S/C18H18F3NO4/c19-18(20,21)13-4-3-5-14(12-13)22-16-7-2-1-6-15(16)17(24)26-11-10-25-9-8-23/h1-7,12,22-23H,8-11H2
IUPAC Name
2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate
SMILES
OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(=C1)C(F)(F)F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Etofenamate.
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Etofenamate is combined with 16-Bromoepiandrosterone.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Etofenamate is combined with 19-norandrostenedione.
5-androstenedioneThe risk or severity of adverse effects can be increased when Etofenamate is combined with 5-androstenedione.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Abciximab.
AcebutololEtofenamate may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Etofenamate is combined with Aceclofenac.
AcemetacinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Acenocoumarol.
AcetaminophenEtofenamate may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,692,818.

General References
Not Available
External Links
KEGG Drug
D04102
PubChem Compound
35375
PubChem Substance
310264945
ChemSpider
32560
ChEBI
94731
ChEMBL
CHEMBL1451633
Drugs.com
Drugs.com Drug Page
Wikipedia
Etofenamate
ATC Codes
M02AA06 — Etofenamate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedDiagnosticDermatitis, Photocontact1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00936 mg/mLALOGPS
logP3.53ALOGPS
logP4.86ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)15.12ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.79 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity89.88 m3·mol-1ChemAxon
Polarizability35.57 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Trifluoromethylbenzenes / Aminobenzoic acids and derivatives / Aniline and substituted anilines / Benzoyl derivatives / Vinylogous amides / Amino acids and derivatives / Carboxylic acid esters / Secondary amines / Dialkyl ethers / Monocarboxylic acids and derivatives
show 6 more
Substituents
Aminobenzoic acid or derivatives / Benzoate ester / Trifluoromethylbenzene / Benzoyl / Aniline or substituted anilines / Vinylogous amide / Amino acid or derivatives / Carboxylic acid ester / Carboxylic acid derivative / Secondary amine
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on June 10, 2014 11:10 / Updated on October 01, 2018 14:44